KalVista Pharmaceuticals

(NASDAQ) KALV

Current Price$26.65

Market Cap$1.37B

Since IPO (2016)+218%

5 Year+7%

1 Year+96%

1 Month+35%

KalVista Pharmaceuticals Financials at a Glance

Market Cap

$1.37B

Revenue (TTM)

$75.04M

Net Income (TTM)

$167.18M

EPS (TTM)

$-4.00

P/E Ratio

-6.66

Dividend

$0.00

Beta (Volatility)

0.67 (Low)

Dividend

$0.00

Beta (Volatility)

0.67 (Low)

Price

$26.65

Volume

5,120,809.73

Open

$26.66

Price

$26.65

Volume

5,120,809.73

Open

$26.66

Previous Close

$26.65

Daily Range

$26.64 - $26.69

52-Week Range

$9.83 - $26.76

Dividend

$0.00

Beta (Volatility)

0.67 (Low)

Price

$26.65

Volume

5,120,809.73

Open

$26.66

Previous Close

$26.65

Daily Range

$26.64 - $26.69

52-Week Range

$9.83 - $26.76

KALV News

Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement

Josh Kohn-LindquistApr 29, 2026

KALV: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About KalVista Pharmaceuticals

Industry

Biotechnology

Sector

Health Care

Employees

275

CEO

Ben Palleiko, MBA

Website

www.kalvista.com

Headquarters

Cambridge, MA 02142, US

KALV Financials

Key Financial Metrics (TTM)

Gross Margin

69%

Operating Margin

-2%

Net Income Margin

-2%

Return on Equity

-190%

Return on Capital

-62%

Return on Assets

-50%

Earnings Yield

-15.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.37B

Shares Outstanding

51.22M

Volume

5.12M

Avg. Volume

2.37M

Financials (TTM)

Gross Profit

$67.54M

Operating Income

$171.84M

EBITDA

$170.38M

Operating Cash Flow

$81.62M

Capital Expenditure

$1.71M

Free Cash Flow

$83.33M

Cash & ST Invst.

$300.21M

Total Debt

$151.57M

KalVista Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2026YOY CHG

Revenue

$59.92M

N/A

Gross Profit

$54.15M

N/A

Gross Margin

90.36%

N/A

Market Cap

$1.37B

N/A

Market Cap/Employee

$9.10M

N/A

Employees

150

N/A

Net Income

$5.37M

+88.9%

EBITDA

$12.72M

+69.1%

Quarterly Fundamentals

Name

Q3 2026YOY CHG

Net Cash

$16.01M

-93.5%

Accounts Receivable

$11.30M

+20.2%

Inventory

$3.43M

N/A

Long Term Debt

$269.02M

+6101.4%

Short Term Debt

$15.19M

+951.9%

Return on Assets

-49.85%

N/A

Return on Invested Capital

-62.37%

N/A

Free Cash Flow

$45.52M

+238.7%

Operating Cash Flow

$45.36M

+238.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OLMAOlema Pharmaceuticals, Inc.

OLMAOlema Pharmaceuticals, Inc.$14.32-0.62%

OMEROmeros Corporation

OMEROmeros Corporation$15.06+3.15%

RAPTRAPT Therapeutics, Inc.

RAPTRAPT Therapeutics, Inc.$58.01+0.00%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$10.64-3.80%

RIGLRigel Pharmaceuticals, Inc.

RIGLRigel Pharmaceuticals, Inc.$29.40+1.73%

ADCTADC Therapeutics S.A.

ADCTADC Therapeutics S.A.$3.83+1.32%

FDMT4D Molecular Therapeutics, Inc.

FDMT4D Molecular Therapeutics, Inc.$9.09+2.48%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

AAPLApple

AAPLApple$280.14+0.03%

SOFISoFi Technologies

SOFISoFi Technologies$16.43+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

NIONio

NIONio$5.91-0.08%

Questions About KALV

What is the current price of KalVista Pharmaceuticals?

KalVista Pharmaceuticals is trading at $26.65 per share.

What is the 52-week range for KalVista Pharmaceuticals?

Over the past 52 weeks, KalVista Pharmaceuticals has traded between $9.83 and $26.76.

How much debt does KalVista Pharmaceuticals have?

As of the most recent reporting period, KalVista Pharmaceuticals reported total debt of $284.21M.

How much cash does KalVista Pharmaceuticals have on hand?

KalVista Pharmaceuticals reported $229.34M in cash and cash equivalents in its most recent financial results.

What is KalVista Pharmaceuticals’s dividend yield?

KalVista Pharmaceuticals does not currently have a dividend yield.

KalVista Pharmaceuticals

KalVista Pharmaceuticals Financials at a Glance

KALV News

Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement

KalVista Posts 154% Expense Jump in Q1

Can KalVista Pharmaceuticals Stock Fly Higher?

Why KalVista Pharmaceuticals Stock Skyrocketed 115% Today

KALV: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About KalVista Pharmaceuticals

KALV Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

KalVista Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KALV

What is the current price of KalVista Pharmaceuticals?

What is the 52-week range for KalVista Pharmaceuticals?

How much debt does KalVista Pharmaceuticals have?

How much cash does KalVista Pharmaceuticals have on hand?

What is KalVista Pharmaceuticals’s dividend yield?

Premium Investing Services